Keywords: Parmaxcis, Bronchitol, Cystic fibrosis, CF, UK. NICE

UK's NICE reverses earlier negative decision on Pharmaxis' CF treatment Bronchitol

Article | 28 October 2012

Print This

Australia’s Pharmaxis (ASX: PXS) says that the UK drugs watchdog the National Institute for Health and Clinical Excellence ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in